Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR Mutations”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03210714
What this trial is testing

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell Tumor+29 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Ended earlyNCT04003623
What this trial is testing

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Who this might be right for
Advanced or Metastatic Solid TumorsFGFR MutationsFGFR Translocations
Incyte Corporation 1
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Large-scale testing (Phase 3)Ended earlyNCT03773302
What this trial is testing

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Mutation
QED Therapeutics, a BridgeBio company 48
Testing effectiveness (Phase 2)Ended earlyNCT02706691
What this trial is testing

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Who this might be right for
FGFR Gene AmplificationFGFR1 Gene AmplificationFGFR2 Gene Amplification+7 more
University of Chicago 1
Not applicableEnded earlyNCT05052372
What this trial is testing

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Who this might be right for
Bladder CancerUrothelial CarcinomaTransitional Cell Carcinoma+10 more
xCures 2
Early research (Phase 1)Active Not RecruitingNCT05567185
What this trial is testing

Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

Who this might be right for
Urinary Bladder NeoplasmsReceptors, Fibroblast Growth Factor
Janssen Pharmaceutical K.K. 5
Not applicableWithdrawnNCT01888562
What this trial is testing

Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

Who this might be right for
Endometrial Neoplasms
Washington University School of Medicine
Testing effectiveness (Phase 2)UnknownNCT04936295
What this trial is testing

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

Who this might be right for
Breast Cancer
Sun Yat-sen University 61
Early research (Phase 1)Ended earlyNCT04965818
What this trial is testing

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Who this might be right for
Advanced or Metastatic Solid Tumors Irrespective of Gene AlterationsNon-Small Cell Lung CancerKRAS Gene Mutation
Taiho Oncology, Inc. 38
Testing effectiveness (Phase 2)Ended earlyNCT04003610
What this trial is testing

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Who this might be right for
Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
Incyte Corporation 7
Early research (Phase 1)Ended earlyNCT01948297
What this trial is testing

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

Who this might be right for
Solid Tumours
Debiopharm International SA 77
Testing effectiveness (Phase 2)UnknownNCT06022289
What this trial is testing

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Who this might be right for
Solid TumorFGF Receptor Gene MutationFGF Amplification+2 more
Tianjin Medical University Second Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT02160041
What this trial is testing

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

Who this might be right for
Solid TumorHematologic Malignancies
Novartis Pharmaceuticals 84
Testing effectiveness (Phase 2)Study completedNCT05253807
What this trial is testing

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Incyte Corporation 8
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06530823
What this trial is testing

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

Who this might be right for
Biliary Tract CarcinomaCholangiocarcinoma
Eastern Hepatobiliary Surgery Hospital 38
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Testing effectiveness (Phase 2)Looking for participantsNCT07265947
What this trial is testing

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Who this might be right for
Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences, Inc 230
Early research (Phase 1)Active Not RecruitingNCT06160752
What this trial is testing

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Who this might be right for
Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid Tumor+1 more
Tyra Biosciences, Inc 40
Testing effectiveness (Phase 2)Ended earlyNCT02150967
What this trial is testing

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Mutation
QED Therapeutics, a BridgeBio company 143
Next Page